anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
UNLABELLED: Streptococcus mitis/oralis can cause invasive diseases, including bloodstream infections. However, existing research primarily focuses on specific populations, and limited studies have been conducted on the prevalence of bloodstream infection caused by S. mitis/oralis across the entire pediatric population. Therefore, clinical data of S. mitis/oralis isolated from blood samples at Children's Hospital, Zhejiang University School of Medicine, during the period 2019-2023 were collected retrospectively to provide a comprehensive understanding of the clinical characteristics and drug resistance patterns associated with bloodstream infections caused by S. mitis/oralis in pediatric populations. There were 57 (43.5%) instances of contamination across various departments, indicating a relatively dispersed pattern. Bloodstream infections caused by S. mitis/oralis are notably prevalent among pediatric patients with hematological diseases and tumors. The susceptibility rates of the 74 S. mitis/oralis isolates to different antibiotics were as follows: penicillin (23%), ceftriaxone (74.3%), levofloxacin (86.5%), chloramphenicol (89.2%), erythromycin (27%), clindamycin (67.6%), linezolid (100%), and vancomycin (100%). Notably, 21.6% of the isolates exhibited multi-drug resistance (MDR). The predominant mode of MDR in S. mitis/oralis infections was identified as resistance to β-lactams, erythromycin, and clindamycin. The observed low susceptibility rate to penicillin, coupled with the emergence of MDR strains, underscores the imperative for continuous monitoring of the evolving antimicrobial resistance in S. mitis/oralis.
IMPORTANCE: Existing research primarily focuses on specific populations, such as those with hematopathy or tumors, who experience Streptococcus mitis/oralis bacteremia. Limited studies have been conducted on the prevalence of bloodstream infections caused by S. mitis/oralis across the entire pediatric population. It was found that the contamination rate of S. mitis/oralis isolated from blood cultures was notably high in our study. Therefore, this study evaluated the clinical characteristics and drug resistance patterns of bloodstream infections caused by S. mitis/oralis across the entire pediatric populations, explicitly excluding cases of blood culture contamination. The observed low susceptibility rate to penicillin, coupled with the emergence of multi-drug-resistant strains, underscores the imperative for continuous monitoring of the evolving antimicrobial resistance in S. mitis/oralis.
PROBLEM TO BE SOLVED: To prepare a preparation for external use for the skin, capable of exhibiting and imparting an excellent effect on the prevention of the skin from getting older and a skin beautifying effect by using one or more kinds selected from mevalonic acids and its specific derivatives with a specific polyhydric alcohol in combination. SOLUTION: This external preparation is obtained by compounding one or more kinds selected from mevalonic acids and mevalonic acid lactone compounds with one or more kinds selected from a group consisting of polyhydric alcohols having OH groups of >=4 in a molecule and glucopyranoside derivatives of the formula (R is a 2-8C alkyl). As the mevalonic acid, R(-)- mevalonic acid, which is easily available, is preferable. Further, mevalonic acid lactone is easily converted into mevalonic acid by hydrolysis. As an example of the polyhydric alcohol, diglycerin, glucose, trehalose, etc., is cited. As an example of the glucopyranoside derivative of the formula, ethyl glucoside or propyl glycoside is cited. The external preparation is composed of mevalonic acid, etc., in an amount of about 0.01-2.0wt.% and a polyhydric alcohol, etc., in an amount of about 0.01-3.0wt.%.
Caution should be exercised in administering of Intralipid® 20% (A 20% Intravenous Fat Emulsion) to patients with severe liver damage, pulmonary disease, anemia or blood coagulation disorders, or when there is danger of fat embolism.

WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.
Bone-modifying agents (BMAs) are integral to managing patients with advanced cancer. They improve quality of survival by reducing skeletal-related events, treating hypercalcaemia and chemotherapy-induced bone loss (Coleman in Clin Cancer Res 12: 6243s-6249s, 2006), (Coleman in Ann Oncol 31: 1650-1663, 2020). Two decades ago, medication-related osteonecrosis of the jaw (MRONJ) was first reported following BMA therapy (Marx in J Oral Maxillofac Surg 61: 1115-1117, 2003). The risk of MRONJ extends over a decade following BMA treatment with bisphosphonates, complicating dental care such as extractions. In addition, MRONJ has been reported following additional therapies such as antiangiogenic agents, cytotoxic agents, immunotherapy, and targeted agents. The use of BMAs in the curative and adjuvant cancer setting is increasing, consequently the implication of MRONJ is growing. Over the past 20 years, the literature has consolidated major risk factors for MRONJ, the pathophysiology and management strategies for MRONJ. Our review aims to document the development of MRONJ preventative and management strategies in cancer patients receiving a BMA. The authors advocate the incorporation of dental oncology strategies into contemporary cancer care, to optimise long-term quality of survival after cancer treatment.
PURPOSE: To diagnose the possibility of morbidness of cancer from the hue of precipitate by adding the mixture of a nitric acid solution of monovalent mercury salt and a sulfuric acid solution of bivalent silver salt into a small quantity of urine of a subject. CONSTITUTION: Reaction of a Millon reagent and a phenolic metabolic substance in the urine of cancer patient, non-cancer patient and normal person has correlation with the concentration. Most stabilized red or red brown precipitate is produced for a cancer patient using a mixture of a nitric acid solution of monovalent mercury salt and a sulfuric acid solution of bivalent silver salt mixed with a Millon reagent. The monovalent mercury salt reacts on a phenolic metabolic substance to produce a red precipitant but it is susceptible to disturbance by inorganic salts in the sample. The bivalent silver salt does not pertain to the red color reaction but produces a precipitate easily along with inorganic salts. Consequently, the mixture combines the advantages of both liquids.
BACKGROUND: Reduced exercise capacity is a prognostic indicator of adverse outcomes in patients with acute myocardial infarction (AMI). However, few studies have evaluated the effectiveness of comprehensive cardiac rehabilitation (CR) in this population. This study aimed to clarify the efficacy of comprehensive CR in patients with AMI and reduced exercise capacity.
METHODS AND RESULTS: This cohort study included 610 patients with AMI who underwent percutaneous coronary intervention. Major adverse cardiovascular events (MACE) were compared between patients who participated in comprehensive outpatient CR for 150 days (CR group; n=430) and those who did not (non-CR group; n=180). During the mean (±SD) follow-up period of 6.1±4.0 years, the CR group exhibited a lower incidence of MACE (log-rank P=0.002). Multivariable analysis revealed that Killip classification, diuretics at discharge, and participation in comprehensive CR were independently associated with MACE. The CR group was further divided into 2 groups, namely reduced exercise capacity (% predicted peak V̇O2<80%; n=241) and preserved exercise capacity (≥80%; n=147), based on the initial cardiopulmonary exercise test. Despite distinct exercise capacities, the incidence of MACE was comparable and physical parameters improved similarly after comprehensive CR in both groups.
CONCLUSIONS: Comprehensive CR in patients with AMI effectively reduced the incidence of MACE regardless of initial exercise capacity. Cardiologists should actively encourage patients with low exercise capacity to participate in comprehensive CR.
Conventional Physical Therapy (CPT) was administered to the control group three times per week for six weeks (45 minutes per session). CPT treatments such as mat activities, assisted movements, weight-bearing strategies, and gymnasium training were given to the control group.
PURPOSE: A foot pack composition containing natural aroma oil, natural mineral, fermented extract of herbal plants or the like is provided. It prevents harmful bacteria from thriving between toes, discharges waste matter and toxin in the skin, imparts moisturizing action to the skin and promotes blood circulation. CONSTITUTION: The foot pack composition comprises: 3 to 5% by weight of natural aroma oil, 5 to 15% by weight of natural mineral and 5 to 15% by weight of fermented extract of herbal plants. The natural aroma oil is Menthae Herba, Lavandula officinalis, Lemongrass, tea tree and Cupressus sempervirens. It is in the shape of cream, gel or peel-off. The herbal plants are selected from Artemisia capillaris Thunb, pine needle, Pueraria lobata, Angelicae gigantis Radix, Ligularia fischeri or the like.
FIELD: dentistry.SUBSTANCE: invention relates to methods of oral care. Method involves daily oral treatment with the first and second REMARS compositions by alternate exposure, without mouth rinsing with water between the treatments. Depending on the oral condition, the treatment is carried out first with a reducing composition for normalizing the oral cavity pH and then with a stabilizing composition. If the pH value of the oral cavity is the reducing agent, a composition with pH from 3.0 to 8.0 is used, and the stabilizing composition is a composition with pH from 6.0 to 10.0. If the pH value of the oral cavity is used as a reducing composition with pH 6.0 to 10.0, and the stabilizing composition is a composition with pH from 3.0 to 8.0. If the neutral pH value of the oral cavity is used as the reducing composition with pH from 6.8 to 7.2, and the stabilizing composition is a composition with pH from 7.3 to 7.8. Difference between the pH of the reducing and stabilizing compositions ranges from 0.1 to 7 units.EFFECT: technical result is higher efficiency of oral treatment; advantage of the method is possibility of prolonged treatment of oral cavity in domestic conditions after selection of preparations by dentist; observing the doctor's recommendations, the patient will achieve a healthy level of the oral health by using a restoring and stabilizing agent.1 cl
The recommended dosage and duration of treatment for infections in pediatric patients are described in the following chart; the total daily dose for all infections is 14 mg/kg, up to a maximum dose of 600 mg per day. Once-daily dosing for 10 days is as effective as BID dosing. Once-daily dosing has not been studied in skin infections; therefore, cefdinir for oral suspension USP should be administered twice daily in this infection. Cefdinir for oral suspension USP may be administered without regard to meals.

1. Pediatric patients who weigh ≥ 43 kg should receive the maximum daily dose of 600 mg.
The purpose of the study is to see how effective the combination of chemotherapy drugs VP-16, chlorambucil, dexamethasone, and vincristine is for patients who have blood cancers that have returned or not responded to prior treatment. Some patients may also receive a medication called rituximab if their doctor thinks it is appropriate. This drug combination will be given to study participants in a low dose continuous basis. The study will also collect information about the side effects of the above drug combination on patients with these types of cancers. Previous studies on patients with non-Hodgkin's lymphoma indicate that some patients treated with this drug combination achieved a high response. The aim of this study is to test this drug combination in a controlled setting.
FIELD: food production process. ^ SUBSTANCE: production method of the product with chondroprotective action includes mincing, defattening and processing with ferments with proteilytic action from hepatopancreas of king crab chodrostei collagen tissues. Herewith the ration of s is consequently 1 : (197) : (3010). Processing with ferments is performed in liquid extract of rose hips or flowers of wild chamomile or sage leaves with weight fraction of dry materials 25%. ^ EFFECT: product quality and process effectiveness increase. ^ 1 tbl, 12 ex
In a method, a system and a computer program product to control a medical imaging apparatus or to extend a control method for such an apparatus, the divided into different segments. A physical segment includes all control modules that are dependent on the platform of the medical apparatus. A logical segment includes all control modules that are independent of a platform. The logical segment of the control method is swapped out to an additionally provided auxiliary control computer while the physical segment remains on the (previous) control computer. At the previous control computer a data transfer module is provided that receives data of the auxiliary control computer and relays it to the medical apparatus for control. The auxiliary control computer advantageously possesses standardized interfaces.
The invention discloses a digestion-promoting and stomach-strengthening decoction which is prepared from the raw materials of, by weight: 13-17 parts of pilose asiabell root, 10-14 parts of upright ladybell root, 10-14 parts of hawthorn fruit, 4-8 parts of lemon slices, 1-5 parts of golden thread, 7-11 parts of medicinal evodia immature fruit, 10-14 parts of parched hawthorn fruit, 7-11 parts of vinegar powder, 4-8 parts of panax notoginseng, 28-32 parts of ark shell, 13-17 parts of common bombax root, 1-5 parts of the cajanus cajan, 8-12 parts of medicinal fermented mass, 4-8 parts of ghostplant wormwood herb, and 1-5 parts of Chinese brake herb. According to the invention, the parched hawthorn fruit and the hawthorn fruit have functions of gastric motility increasing, gastric emptying promoting, and fullness symptom ameliorating. Upright ladybell root has functions of stomach-Yin nourishing and digestion difficulty symptom ameliorating. Panax notoginseng has a gastric mucosa repairing function. Golden thread has functions such as killing intragastric helicobacter pylori. Vinegar powder is solid vinegar. Lemon has an appetite promoting function. The whole formula is reasonably and scientifically formulated, and has a good curative effect against digestion difficulty, fullness, and stomachache symptoms caused by acute or chronic gastritis. The decoction has no toxic or side effect.
Participants were assigned to intervention and control groups according to the randomization list previously prepared by the researchers. All participants were first informed about the study and their informed consent was obtained. Participant Information Form, Geriatric Anxiety Scale, Psychological Well-Being Scale, and Geriatric Depression Scale were filled out by all participants.

The elderly in the intervention group were divided into 5 groups of 10 and a time was determined for the session in cooperation with the participants in each subgroup. A 60-minute therapy session was administered by the occupational expert. The applications were carried out in a total of 7 sessions as a daily session. The control group was not subjected to any application. Geriatric Anxiety Scale, Psychological Well-Being Scale, and Geriatric Depression Scale were refilled for the second time in all elderly on the 7th day after the application.
The present disclosure generally relates in certain embodiments to a magnetic imaging kit for biochemical sensing, e.g., for detection of analytes, via magnetic imaging techniques. For instance, in one set of embodiments, the kit comprises a collection of magnetic imaging agents (e.g. superparamagnetic iron oxide nanoparticles) and linker species (e.g. a catechol, phosphothreonine, and/or derivative thereof) with a molecular weight of less than or equal to 1000 Da, or less than or equal to 500 Da. The magnetic imaging agents may sense the presence of an analyte via aggregation or disaggregation of the two or more magnetic imaging agents. In addition, certain aspects are directed to a method of exposing two or more magnetic imaging agents to a region on or in a subject and imaging the region to determine the analyte.
Initially patients will be informed about the procedures. After the guidelines, the hip and knee are palpated to start the joint angles. Then, the knee joint is positioned in extension and remained so throughout the treatment. In addition, the hip joint is bent until the moment that will be perceived a minimum strength of the muscles of the posterior region of thigh and leg (discarding muscle stretching). Neural mobilization is started at the time when the ankle joint will be manipulated in dorsiflexion at a frequency of approximately 20 oscillations per minute, with a pause of 25 seconds of rest. In the last two minutes of therapy, we will include cervical flexion, in order to intend the neuraxis, keeping artuculares amplitudes.
Seven home visit was made to adolescent in the intervention group. In the first and last visits only self-care knowledge and skills of adolescents were evaluated. In the 2.,3.,4.,5. and 6. home visits they received supportive-educational individualised nursing care based on Orem's Self Care Deficit Nursing Theory. The applied nursing interventions varied based on the individual needs and the level of assistance required by each adolescent. Each home visit lasted 30-60 minutes. Adolescents were given an educational booklet containing information about self-care in cystic fibrosis.
Fragile X-associated tremor/ataxia syndrome (FXTAS) is a progressive hereditary neurodegenerative disorder which causes intention tremor and cerebellar ataxia. It typically affects the ageing population. Deep brain stimulation (DBS) is widely accepted in the treatment of common movement disorders and has been trialled in treating rare and complex neurodegenerative disorders. We report a case of a man in his 40s with a long history of tremor affecting his hands. MRI brain revealed high T2 signal in the middle cerebellar peduncles. Genetic testing revealed FMR1 premutation confirming the diagnosis of FXTAS. Subsequently, he was treated with multitarget DBS of the ventralis intermediate nucleus and ventralis oralis posterior nuclei bilaterally, with excellent neurological function at 9 years follow-up. This case suggests multitarget DBS for FXTAS with neurophysiology-guided DBS programming can provide excellent long-term tremor suppression in selected patients.
Tropisetron 5mg iv. at the start of skin closure.Sham transcutaneous electrical acupoint stimulation.Dexamethasone 10mg i.v.after induction.
1,187,830. Pharmaceutical composition comprising polynucleotides. MERCK & CO. Inc. 15 Dec., 1967 [23 Dec., 1966; 25 May, 1967; 9 Aug., 1967; 22 Nov., 1967], No. 57079/67. Heading A5B. [Also in Division C3] A pharmaceutical composition for administration to persons and animals to induce in them the formation of interferon as a microbe-resisting substance, comprises a pharmaceutical carrier and a multistranded polynucleotide substantially free from proteins and other substances that inhibit the formation of interferon when the polynucleotide is administered to humans or animals or is added to a culture of living animal or human cells. The polynucleotide is suitably a polymer resulting from the complexing of two of the following homopolynucleotides:-polyadenylic acid, polyuridylic acid, polyinosinic acid, polycytidylic acid and cytidylcytidine; or is a ribonucleic acid that has been released by phenol from a ribonucleic acid complex elaborated by the growth of P. funiculosum; or the polynucleotide may be released from reovirus type 3 virions or the polynucleotide may be the isolated replicative intermediate form elaborated in living cells infected with a DNA or RNA virus.
Hydrogel compositions are provided (a) that have a continuous hydrophobic phase and a discontinuous hydrophilic phase, (b) that have a discontinuous hydrophilic phase and a continuous hydrophilic phase, or (c) that are entirely composed of a continuous hydrophilic phase. The hydrophobic phase, if present, is composed of a hydrophobic polymer, particularly a hydrophobic pressure-sensitive adhesive (PSA), a plasticizing elastomer, a tackifying resin, and an optional antioxidant. The discontinuous hydrophilic phase, if present, is composed of a crosslinked hydrophilic polymer, particularly a crosslinked cellulosic polymer such as crosslinked sodium carboxymethylcellulose. For those hydrogel compositions containing a continuous hydrophilic phase, the components of the phase include a cellulose ester composition or an acrylate polymer or copolymer, and a blend of a hydrophilic polymer and a complementary oligomer capable of hydrogen bonding thereto. Films prepared from hydrogel compositions containing or entirely composed of the aforementioned continuous hydrophilic phase can be made translucent, and may be prepared using either melt extrusion or solution casting. A preferred use of the hydrogel compositions is in wound dressings, although numerous other uses are possible as well.
PURPOSE:To provide an emulsified preparation composed of water, iodized oil, a water-soluble organic iodine compound, a surface active agent and a water-soluble active component, having high stability with time, and useful as a remedy for the diseases of the lymphatic system. CONSTITUTION:(A) 2.0-99pts.wt., preferably 87-33pts.wt. of an iodized oil (e.g. iodized olive oil, poppy oil, etc.) is mixed homogeneously with (B) 0.01-25pts.wt., preferably 0.1-15pts.wt. of a surface active agent (e.g. Tween 80). Separately, a water-soluble organic iodine compound (e.g. meglumine amidotrizoate) is dissolved in refined water to obtain an aqueous solution having a specific gravity of 1.2-1.5 and a concentration of 20-90w/w%. An active component (e.g. a carcinostatic agent such as actinomycin) is added and dissolved in the above solution at a concentration of 0.05-10w/w%, preferably 0.1-5w/w%. The iodized oil mixture is emulsified with the aqueous solution by a homogenizer for 10-60min to obtain the objective preparation. The volume ratio of the aqueous solution to the iodized oil is selected to 0.01-4.
PURPOSE: A pharmaceutical composition containing outer membrane vesicles for anticancer is provided to effectively deliver an anticancer agent into cells and enable cancer treatment of high specificity. CONSTITUTION: An outer membrane vesicles(OMVs) for anti-cancer comprises: an outer membrane proteins(OMPs), a cancer-targeting ligand conjugated to the outer membrane vesicles; and an anticancer agent. The outer membrane vesicle is derived from gram-negative bacteria such as E.coli. The OMP is cytolysin A. The anticancer is docetaxel. A composition for anti-cancer contains pharmaceutically effective amount of OMVs and a pharmaceutically acceptable carrier.